文献速递糖尿病

SGLT2抑制对HNF1A-MODY(MODY3)和2型糖尿病患者高血糖钳夹期间尿糖的影响

Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2025-01-01

本研究为随机双盲交叉试验,纳入11例HNF1A-MODY和10例2型糖尿病患者,在10、14、18 mmol/L三步高血糖钳夹期间比较急性SGLT2抑制(恩格列净25 mg)与安慰剂对尿糖排泄的影响。结果显示SGLT2抑制使两组尿糖排泄均增加,组间效应无显著差异,作者认为SGLT2抑制是HNF1A-MODY相关的降糖治疗策略。

要点

  • SGLT2抑制使HNF1A-MODY患者3小时尿糖排泄增加24.5 g(95%CI 20.6, 28.3)。
  • SGLT2抑制使2型糖尿病患者3小时尿糖排泄增加23.5 g(95%CI 20.4, 26.5)。
  • 两组间SGLT2抑制的尿糖排泄效应无显著差异(差值1.0 g,95%CI -3.5, 5.6;P=0.6)。

核心结论

  • SGLT2抑制在HNF1A-MODY患者中对尿糖排泄有显著效应,提示其可能是HNF1A-MODY相关的降糖治疗策略。

研究设计与样本

  • 随机双盲交叉研究,纳入11例HNF1A-MODY患者(年龄49±15岁,GFR 113±18 mL/min)和10例2型糖尿病患者(年龄63±7岁,GFR 103±27 mL/min)。
  • 受试者在钳夹前2小时接受恩格列净25 mg或安慰剂,进行三步高血糖钳夹,目标为1小时10、14、18 mmol/L血糖。

主要发现

  • 3小时高血糖钳夹期间,SGLT2抑制使HNF1A-MODY组尿糖排泄增加24.5 g(95%CI 20.6, 28.3),2型糖尿病组增加23.5 g(95%CI 20.4, 26.5)。
  • SGLT2抑制的效应在两组间无显著差异(差值1.0 g,95%CI -3.5, 5.6;P=0.6)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pathogenic variants of HNF1A cause maturity-onset diabetes of the young type 3 (HNF1A-MODY; also known as MODY3). Individuals with HNF1A-MODY are primarily treated with sulfonylureas; however, little is known about the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors in HNF1A-MODY. Interestingly, HNF1A-MODY is associated with increased glucosuria, which has been attributed to lower expression of SGLT2 as observed in HNF1A-knockout mice. We investigated the impact of acute SGLT2 inhibition on glucosuria in individuals with HNF1A-MODY or type 2 diabetes. RESEARCH DESIGN AND METHODS: In a randomized, double-blind, crossover study, individuals with HNF1A-MODY or type 2 diabetes underwent two three-step hyperglycemic clamps targeted at 1-h periods of 10, 14, and 18 mmol/L glucose with and without acute SGLT2 inhibition (25 mg empagliflozin or placebo administrated 2 h before clamp procedures). RESULTS: Eleven individuals with HNF1A-MODY (age [mean ± SD] 49 ± 15 years; glomerular filtration rate [GFR; mean ± SD] 113 ± 18 mL/min) and 10 individuals with type 2 diabetes (age 63 ± 7 years; GFR 103 ± 27 mL/min) were included. During the 3-h hyperglycemic clamp, SGLT2 inhibition increased urinary glucose excretion in both groups (HNF1A-MODY: 24.5 g [95% CI 20.6, 28.3]; type 2 diabetes: 23.5 g [95% CI 20.4, 26.5]). The effect of SGLT2 inhibition was not significantly different between the groups (1.0 g [95% CI -3.5, 5.6]; P = 0.6). CONCLUSIONS: The robust effect of SGLT2 inhibition on urinary glucose excretion in participants with HNF1A-MODY points to SGLT2 inhibition as a relevant glucose-lowering treatment strategy in individuals with HNF1A-MODY.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Maagensen H, Jensen JS, Høyerup SO, et al. Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes. Diabetes Care. 2025. PMID: 40608360. doi:10.2337/dc25-0737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。